EverYuth Naturals

Cadila Healthcare, part of the ZydusCadila group, is reportedly planning to launch an indigenously developed molecule for diabetes dyslipidemia, which is expected to be called Saroglitizar. The company has been working on a new molecule since 2004.

New Delhi: Drug firm, Zydus Cadila, has announced that it has launched a migraine drug in the US.The firm said that it had launched Zolmitriptan, an orally disintegrating tablet used for the treatment of migraine, in the American market after ...

On Track for Sustainable Cash Flow and Profitability TORONTO , May 14, 2013 /CNW/ - Microbix Biosystems Inc. (MBX.TO), a biotechnology company developing innovative biological products and technologies, today reported financial results for its ...

GROUP A A A B B 489.7(486.35) 839-469 (5) A C C 1212.75(1188.7) 1514-1105 (31) Abg Shipyard 320.35(320.75) 415-232 (0) Abirlanuv 968.85(958.9) 1190-726 (6) Acl 188.75(187.25) 220-135 (98) Adani Enter 219.9(215.75) 319-151 (206) Akruti City 132.45(131.55) ...

It has made investments in downstream steel projects in India, driven by the potential of its steel market States raise tariffs, but discoms still in doldrums Subsidised power to agriculture, transmission losses and mounting debt burden weigh heavily on their ...

(Zydus Cadila) has received tentative approval from the USFDA for two anti-hypersensitive drugs. The approval has been given for Amlodipine Besylate and Benazepril Hydrochloride capsules in the strengths of 2.5 mg/10 mg, 5 mg/10 mg, 5 mg/20 mg and ...

Cadila Healthcare has approved the merger of Zydus Animal Health (ZAHL), Liva Healthcare (LHL) and Zydus Pharmaceuticals (ZPL) with itself. Gujarat based pharmaceutical company's board and the Board of Directors of ZAHL, LHL and ZPL have reached the ...

Cadila Healthcare is currently trading at Rs 747.80, up by 6.45 points or 0.87% from its previous closing of Rs 741.35 on the BSE. The scrip opened at Rs 749.00 and has touched a high and low of Rs 750.85 and Rs 746.05 respectively. So far 253 ...

Zydus Cadila has received the final approval from the USFDA to market Ranitidine HcI injection 25 mg/ml. The estimated sales in 2012 as per IMS for Ranitidine HcI injection USD 5.4 million. The group now has 76 approvals and has so far filed 172 ANDAs since ...